2012 įIJūŻȇıȐƶĐ¥Ơĉǔ²óĄîű
ǔ²ē‘Ąîű
ǛĥǎǡÔǝċĐ ÔĐɏ ȐƶĐȭij
‡þ Ǐ¸
*5'
ǜ* 2012 į 9 ų; 2014 į 8 ųź2#bE^) Friedrich-Alexander ċĐd{‚qM=HC
}‚P‚ɳŸ‰ɵHC}‚P‚ċĐɴ) Institute of Clinical and Experimental Pharmacology and
Toxicology '
"ɵMartin Fromm Ţř)ŘĞ)6$ǔ²AȒ2ɶǔǠ_„u*m}
sfEbɮ$ÔȐò)nj–¬ƹ'ɛ=Ăǖ
:,ȇıǔǠ$"ɵƭ'ǷȌ'Ȱě'ì2>
=J_L‚ɮ'ƫƪAĸ"ȐƬa}‚Vt„Z„A›J_L‚$ȐƬ)nj–¬ƹ'
"ǔ
ǠAȒ2ɶ
HC}‚P‚'
"
HC}‚P‚ɳErlangenɴ*ÖbE^ƒhEH‚ħ)ÓɏɵM~VuVu„O]a8
67
)șŻĩ#ǒ;>=d{‚qM;ÓȗǮ 20 km '=ċĐƼ#ɶbE^$+u‚
\]MȔɊŴê#ɵ>:<88uEc„&ãĀȔɊƘ'&<ɵȾɣ'*ŬĩȔ
ŒƽɎƸ'džɗ>"=h‚qMɳBambergɴɵɪƇǚə>=hEEaɳBayreuthɴɵ
;'Œ)ȔŽ3Ɛ<ūŻ™ȝºĖ6Ċ„_‚nMɳRothenburg ob der Tauberɴ<2
ɶHC}‚P‚)…Ĭ*m}‚O‚ýũ$ð+>ɵȣȞȍ8Ŧƶ&%éħ#=v{‚
p‚8CFMVnM&%)Öɏ$*&<ɋ$)$#ɶ2q~‚&%bE^Óɏ
*ȷ¤)0$B%&Įɓİ"2ɵHC}‚P‚ïȼ*Įý$ǹ8&ɠý;
&"2ɶĠÓ'Ȓ$ğɲĤɅ&<)ȯɚAĦƟ>ɵĤ)ˆ'*ŽƂ"ã
Āƪ$=ɯºŭč&ąŎ<2ɶȷ¤=ýĹ6CoV):$Ȟ
$;ɵm}‚L]T{ɻT{hE^ɳFränkische Schweizɵm}‚O‚)VEVɴ$ð+>"2
ɶbE^'*œ'6SMX‚)VEVɵ$:'Ĥ8ȯ=$?AVEV'¯=
$=:#ɵūŻ#6Ů&;)ƼŽ8ɧùƔAƐ$?Ağ˜ɐ8ğƖō$ð-)'
Ⱦʼnț#*&$ʼn2ɶHC}‚P‚*Ȕ)ŀ'ċĐǡý"
<ɵ;'ȕǾ
ö8ɖɊx„J„$"ǒ;>=T„x‚V)ŻǙ=$;ɵHC}‚P‚'©4Ǯ 10 †
™2<)™)0$B%*ċĐT„x‚V'ɛ±=$Ȟ@>"2ɶ2ɣƼ'*V
t„^x„J„)C`D[V8qC~‚Nx„J„#=TGm}„)ŻǙ<ɵ>;£Ɔ
'ūŻ;ȶ¢"=ũ6=5HC}‚P‚*)™â)É'ūŻ™)Ť*Ċ:'
ʼn2ɶ
ɳÀǐɷ HC}‚P‚)ȔŽ3ɴ
HC}‚P‚ċĐ'
"
HC}‚P‚ċĐ* 1743 į'ȡǡ>ɵbE^)œ)ċĐ$éƉ'Êȡǽ)êÈ'&B#ċ
Đê
;>"2ɶ2ɵǶèċĐ$"hEH‚ħ#*v{‚p‚ċĐ'ƍ# 2 ǀ
NJ)ȚƊAŗ"
<ɵƾĐƷ6ĊɵǜƣƯNjļ'ɃbE^ȧǓŷɤȭij'*Ɖ
&ú)ĐƷÝÌ"2ɶƭ'E‚b;)ƾĐƷ*œ)M}VAș÷"6Ċ:&
ÙȱAá2ɶ2ɵ|„]i*ýƶLJ'Cm~J'6Ⱦ$6"ɵéM}V
'*ÖCm~J8cEUG~C;)ƾĐƷ62ɶ3 Ɇɚ$Ǔɚ#ɵ>
>)
úƃ6ʼn
Â)…
ƒūżAŽ/"Ċúǩ&ĐƷ$…Ǹ'bE^ȧAĐ/)*š#*ȉń
$&"2ɶ2řƆ*ȋȧ#Ȓ@>)#ɵǜ'$"*ĐɏƷ)ů'ǻ"
Ÿƀ)bE^ȧ*6?B)$ɵȋ¥ȣ)a€„d‚N$"6ȉƋ¥'&<2bE
^ƾĐ$%6ǔǠŎ#)8<$<*01ȋȧ#Ȓ@>ɵ…Ȉ)™'
"6ƭ'Ȋ™*ȋ
ȧăȃ&5ɵbE^ȧA®)*ȴƬ8ɰ”&%ūĭƷƞ)…ɏ'ɞ;>2ɶ
ǜŎģ"ȐƶĐǔǠŎ* 4 ɡĵ")ĵƬ#ɵ1 ɡȇıȐƶĐȭijɵ2 ɡĂǖȐƶĐ
ȭijɵý‰$ 3 ɡŸˆ¼éÅƹ)ĕɱė8ImDV$:'Ã>"2ɶHC}‚
P‚ċĐ)œ)ĵƬ*'6ã#ɒÚ&Ʉ<#=)'ĝ"ɵȐƶĐǔǠŎ*ƓȺLJŨ
ȾLJ&ĵƬ#ɶɵ…Ȉ)©đ#6#ɵșNJ*ãƏå<&
ĵƬ#"6¾ɏ*ɨĭ'y[‚&Ʉ<'&"=$)bE^)ĵƬ)ƭĿ):'
ń2ɶ2ɵ)ǔǠŎ)ɣ*Kitzmann$HC}‚P‚)ýk„Ĩą#<ɵ
'6bE^;$ʼn2ɶY„X„U'Ì"ɵk„6ɚɋ&bE^™'$
"ƌ&6)#ɵHC}‚P‚#6 2
)k„x„J„<2ɶý¸)
™@ɵŮ*k„Ĩą 20 Ÿˆ6$)$#ɶ"ɵȇıȐƶĐȭij'*ǔǠŎ
ɘ) Fromm Ţř)0' Jörg König Ţř$ Renke Maas Ţř) 3 êüǩ"2ɵbE
^#* Professor Ÿĉ'ŭǕ&ŢȀǿtVa*&5ɵĐƷ.)ȭǺAáŗūŻ#>+Á
Ţř8ÍŢ'ĸ=:&ǔǠǽ#6ɵˆDZǔǠó8tVbM$ő'&=$)$#ɶ
bE^)ŢȀǿÆIJ*Šɩɇ5;>"=:#ɵ«6ǒ;&ǜ'$"bE^)
CJ`vC'
=ȊŏǔǠǽ)Lz~CŠĒĔ#=$*ňĉ'ʼn2ɶ
ɳÀǐɸ ǔǠŎ)ĉȝɴ
HC}‚P‚ċĐȇıȐƶĐȭij'
=ȇıȢɱĕŪ)ƴƮ'
ǜHC}‚P‚ċĐȇıȐƶĐȭij.)ƾĐAĪŶƶƺ)…
"
*ɵȐƬnj–¬ƹ'ɛ
=ȇıȢɱAĕŪ"=Ƌɛ#$$#ɶFromm Ţř* Vanderbilt ċĐ'"š
Grant R. Wilkinson ¹Ʒ)‰#ƾĐ>Ǵɱ<ɵȐƬnj–¬ƹǔǠ'
"6Ăǖĕɱ$$
6'ȇıȢɱAĕŪ=$ɒȘ$ "2ɶǜ*)ƾĐAɃ"ƴübE^)ċĐ
'
=ǔǠǽĞ)ȇıȐƶȢɱ)ĕņ'
"ĐB#$ń"2ɶ
bE^#*œ)ƎħɅèȫú$éƉ'ɵ@9= EU ȇıȢɱ؞ɳEU clinical trial directiveɴ
1)
)ŪȒ'¦ɵµĴ™Aĝȱ$ƓȺLJȚƊ)ğ&ȐƬÏŊȢɱ#"6Ɨɱ$éƉ)Ɯ
ȚÆ)‰#ĕŪ=$'&"2ɶ)5ɵ>ŸÈ'Ɠ/ȢɱĕŪ)g„bƄƑ
'ˆ$)$#ɶˆȠ EU ȇıȢɱ؞)Ȥdz'
"ŻǞ#*Ǎƿ2ɵǜ)
ƾĐ¹)ƴƮ$"ʼn$A…Ȟ#ɀ/=$ɵċĐ) 1 ȭijק'
"ȇıȢɱAĕŪ
='*ɵ™ž&<Šȸ"=$$#ɶǜHC}‚P‚ċĐ'ƾĐĸůɵȇ
ıȐƶĐȭij#*Ôī#= Fabian Müller ØƐ¢ǔǠǽ$&"ȇıȢɱA 1 ¡ĕŪ"
2ɶĻ*HC}‚P‚ċĐ'Ǒ¢=ŸÈɵCROɳclinical research organizationɴ'ÑÐ
$<ƗɱƆÐ)Ǵɱ5ɵċĐ#"6ȇıȢɱ)ĕŪäȃ#ɶɵ
ȐƬŒ‹8śȑ&%ȇıȢɱ)ĕɢ)ɈȒ)3&;ɵue„Ux‚a'ɛ=01»"AŻ™
:,…Ǹ'ǔǠ"ĐƷ)•™#Ķá"5njĸ&Ȳŕ$*éė)ǜ
;ș"6ŭ;#ɶĻ):' EU ȇıȢɱ؞'ÇȇıȢɱAĕŪ=$)#=
Ôī*ċĐ)3&;ȖȐ£Ɔ'$"6ɨĭ'd„WɲɵCJ`vC'
=ȊŏǔǠǽ
)ŠĒĔ&ɥƹƮƙ‰'
"ɵ£Ɔ$ċĐ#™žƲĽ)Ǣ“ƷůɵċĐ*&<ŠÅ'
&"=:#ɶ>;)ȁŰ'ɵĕŪ)5)QVa)õɭ6Ì@<ɵbE^'
=
ǔǠǽĞ)ȇıȢɱĕŪŤ*ȾįƢĠ¶ë'=:#ɶ)$*ɵǣ 35 ÷ūŻȇıȐƶ
Đ¥ĐȓǶ¥)úɢT‚tUFw'
"gE`qMċĐȇıȐƶĐȭij) Walter E. Haefeli
Ţř6ȭƦ#ŘŞ"2ɶ&
ƴƮAȹ2"ɵ2014 į'Ũ' EU ȇıȢɱȚ
Ç 2) ŌǡɵȢɱ)~VM'Ă!"ĕŪȘ¡…ɏǨƿÒ>=:'&=$;ɵšļ
*bE^)CJ`vC'
=ȇıȢɱ6Ĉ@")#*&$’Ň>2ɶūŻ'
"6ɵǜ*>;6bE^'
=ȇıǔǠ'ɛŀAĚ"$ń2ɶ
Ȍ$ȐƬ)nj–¬ƹ'ɛ=ǔǠ'
"
ƴüɵǷȌ*ūŻ&%ƁCUCýā'ɞ;ŒƽLJ'ɛŀAɤ5"=$"6ɉȞ#*&
$ń2ɶ)ƶƺ$"ɵǷȌ'Ȱě'ì2>=J_L‚$ð+>=m}sfEbɮµ
Ĵ8ǁǂ’ɜ'Ŵlj&ÎƂAŴ=$ŤĊĄî>"=$6ɛɅ"=$Ǽ2ɶb
E^6)¯ĉ#*&ɵ
ȌĢB'Ȓ+ċœ*ǯȌ$ŽB#ǷȌ6ȳć>"2ɶ
ǜ*>2#ǷȌ$ȐƬ)nj–¬ƹ'
"ǔǠAȒ"2ɶ)#ɲȑû8ưŀǃ)
ƗDŽ'ɌŁ=Cb€c~‚áęªɍŧȐ)cb„AǷȌŔÂƬ2*&J_L‚#
=HlKJ_L‚K€„aɳEGCGɴ$­ƹąèɵƕ$ŵƹąè$Ɠ/"cb„
)ȑƨIJċ¨‰=$AÏƬĕɱ'
"șÂ2
3)
ɶ>&;+ja#*%
ɵ$$AȨ/=5'µĴ™Aĝȱ'ȇıȢɱAĕŪ$?ɵja'
"6Ƿ
ȌAŵƹąè'
"cb„)ȑƨIJ*Ȏ¨&=$ȝĜ>2
4)
ɶc
b„*ƕƥŅɲ5ɵơÒǥ;íß>ļɵƷª¾#*ȮAá'ŹĈÒª)
22ġ.$Śƚ>2ɶ)$*ɵȐƬnj–¬ƹ)Ș&Ûø)…
#=ȐƬȮɑDz
)ɝĘ2*ȦĞŸĉ)xJdWwɛ‹"=$AǗô2ɶȐƬnj–¬ƹƷ=6
…
)Șø$"ɵȾįİǒ;>=:'&)ȐƬa}‚Vt„Z„A›6)#
ɶcb„)ƕƥŅ)ɲ*ɵáÏŖţ':=ƷªȆ)ɃɉAɦ=)#ɵ
;«
;)a}‚Vt„Z„':=ȃÏȻɂ)Ƌƈ·"=#?$)’Ƥ*#2ɶ#
*ɵ
ǷȌ$cb„nj–¬ƹ'ȐƬa}‚Vt„Z„*›"=ɺǜ*HC}‚P‚ċ
ĐȇıȐƶĐȭijƉ&m}sfEb'
$AȪť#ǒ"5ɵŸˆ)$'
"ȐƬa}‚Vt„Z„)ɝʬƹAȨ/"=
"=Đ¥)
<' Fromm Ţř'njȩ$
š÷)ƾĐ)$&<2ɶ
HC}‚P‚ċĐȇıȐƶĐȭij#*ȐƬÏŊ'ɛ‹=6)Aŀ'ɵȐƬa}‚Vt„Z
„ADžƴdzȂǭ$>;AƹȐƬȻɂĕɱǭ)ƈǧAǪËLJ'Ȓ"2ɶšļ
ǔǠ'°>=*@;&ɵäȃ&ɞ<Ċ)a}‚Vt„Z„'
`„Zq„VÒ"
"DžƴdzȂA¬Ō
#6®=:':ɵ$Ȣ3'ǜ*%bE^LJ&6)A
ʼn2ɵ$'ǜ*ŏČ5'ğȅ'DžƴȐƬ)íßAŕ"=ŴƋCdI‚Ȼɂr
o\bɳOATPɴ'ǑNJ"ɵcb„)Ăȵ$&=%AȨ/2ɶÄ5'>2
#'Ąî=ğȅ OATP RnZEo)#ƴü)DžƴǕȥ>"= OATP2B1 '
"ɵ
cb„Aà<Ƚ4AȨ/$?ɵƐŃ&;cb„*»dzȂ¾.$ȏǟ>2
B#ɶ6…
)RnZEo#= OATP1A2 *ƴüHC}‚P‚ċĐ'Ŏģ"=
Hartmut Glaeser ØĆ;ğȅ#)DžƴAĄî2ɵǵƂɁȥ>4?Džƴȥ5;
>&$Ąî)ũĊ&"2ɶ$?ɵOATP1A2 *cb„AĂȵ$"ɨĭ
'ÎƳLJ'dzȂ¾.à<Ƚ4$ǵƂĽ;>2ɶ;'ǷȌ8 EGCG ďü=$
OATP1A2 A›cb„Ȼɂ*Ŵň'ɝĘ>=$ŭ;$&<2ɶ>':<ɵ
ȇıȢɱ#ȝĜ>cb„$ǷȌ)nj–¬ƹ*ǷȌ'ì2>= EGCG &%J_L‚ɮ
OATP1A2 A›ğȅ'
=cb„)íßAɝĘ=$#ƷäȃŅ=ɵ$
Ɵ>#2ɶOATP1A2 )Ƞɀ'*ƝňAŐ:'ɵ$ Fromm Ţř;CbhEVAá
&;ɵǔ²È'ȒȇıȢɱ)ǵƂ$­"ƾЏ'>;)ǒșAȪť$"2$5=
$#2 4)ɶ
;'ɵcb„'
"* OATP1B1ɵOATP1B3ɵŴƋJ\I‚a}‚Vt„Z„ɳOCTɴ
+
1ɵOCT2ɵH /ŴƋJ\I‚—ŜȻɂªɳMATEɴ1ɵMATE2-K :, P-ǫZ‚iM)Ăȵ$&=
%AȨ/"2ɶ)ǵƂɵcb„* OATP1B1 $ OATP1B3 Ÿĉ)ˆȠa}‚
Vt„Z„'
Z„'
"*Ăȵ$&<=$ŭ;$&<2ɶ>)a}‚Vt„
"6ȜñŅ*¨ɵcb„)ȑƨIJ$ȑƧZ‚iMǵèƳAǼŋ=$ɵ>
;a}‚Vt„Z„)cb„)Ȅġdzǥ'
=Ãƛ8¿íß.)ɛ‹*ɨĭ'ğ$
Ǘô>2ɶĕɢɵcb„)ȄM~C}‚V*ǬƵªƩɉɔ'Ⱦ³$&"
<ɵ
ŴƋJ\I‚ǭa}‚Vt„Z„AİǦ'ɝĘ=Tx\U‚$cb„$)nj–¬ƹAȨ/
ȇıȢɱ'
"6ɵTx\U‚)­ƹ*cb„)ª¾ÏŊ'ĺɫ& 5) $Ą
î=$6š÷)ĕɱǵƂAşŗ=6)#ɶ
…ũɵǷȌ8 EGCG OATP1A2 Ÿĉ)ȐƬa}‚Vt„Z„)ƞŅAɝĘ='
"6
ça}‚Vt„Z„)½ÿLJ&ĂȵȐƬAƹ"ƅȟ2ɶš÷ǜƹǷȌ#*ɵ
Ȩ/»")ȐƬa}‚Vt„Z„'
"ɝĘķIJ)ɋ*=6))ɝʬƹAŴ=$
@<2ɶÌ"ɵEGCG ×Ư#"6 OATP2B1 Aì5çȐƬa}‚Vt„Z„'ĝ
"ɝʬƹȥ5;>2ɶ…ȈLJ'J_L‚&%m}sfEbɮ*ơÒǥ;íß
>'hEICqE}k~_Dɨĭ'¨$ǒ;>"2ɶš÷ŭ;'& in
vitro '
=ǷȌ&;,'J_L‚)ȐƬa}‚Vt„Z„ɝĘȃĕɢ'ja'
"ɵĂȵ
ȐƬ)ª¾ÏŊ'ĺɫAÞ1äȃŅ*ơÒǥ'Džƴ=a}‚Vt„Z„Aɟ+¨$Ǽ
;>2ɶ
@<'
ńȿ+ 2 įɚ$ǔ²ŷɚ*$ɚ'ɉÜ"2:'ʼn2ɶǔǠ
'
"8<Ɛ$&@#*<2BɵFromm ŢřAÄ5$=HC}‚P‚ċ
ĐȇıȐƶĐȭij)¹Ʒũ;)Ċ)ÕËAĽ"
4(ɬȨ'ɇ5=$#2ɶ2
ȇıǔǠ'ɛ"*ɵūŻ'
"6Żį 4 ų;Ũ&´ƶŘɕŪȒ>ɵċĐ'
=
ȇıȢɱ)<ũ6Ĉ@"=$$ń2ɶ)ɉƣŷ'<bE^)ċĐ'
=ǔ
ǠǽĞ)ȇıȢɱ)ĕņAĊĠ&<$6ǒ=$#)*ňǺ)#*&$ń
2ɶŲļ'&<2ɵš÷)ƾĐAłȬ"<ɵɂ<Â"ŸſǰĎ
ŢřA*5$=ǛĥǎǡÔǝċĐȐƶĐȭij)¹Ʒũ'ŀ:<ʼnȮƻˆ2ɶ2ş
ŝ2ūŻȇıȐƶĐ¥)¹Ʒũ&;,'ūŻȖȐĨƆÕ¥'Úľǘƻˆ2ɶ
ɳÀǐɹ ȇıȐƶĐ)LjB$ɵǤǽ)æɣ Fromm ¹Ʒɴ
ÝǼťƱ
1)
European Commision. Clinical trials - Directive 2001/20/EC.
<http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf>.
2)
European Commision. Clinical Trials Regulation (CTR) EU No 536/2014.
<http://ec.europa.eu/health/files/eudralex/vol-1/reg_2014_536/reg_2014_536_en.pdf>.
3)
Misaka, S., Miyazaki, N., Fukushima, T., Yamada, S., and Kimura, J.: Effects of green tea extract and
(–)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats. Phytomedicine, 20: 1247-1250
(2013).
4)
Misaka, S., Yatabe, J., Müller, F., Takano, K., Kawabe, K., Glaeser, H., Yatabe, M. S., Onoue, S.,
Werba, J. P., Watanabe, H., Yamada, S., Fromm, M. F., and Kimura, J.: Green tea ingestion greatly
reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther, 95: 432-438
(2014).
5)
Duchin, K. L., Stern, M. A., Willard, D. A., and McKinstry, D. N.: Comparison of kinetic interactions
of nadolol and propranolol with cimetidine. Am Heart J, 108: 1084-1086 (1984).

大阪市立大学 杉本キャンパス地図